@entity379 production in whole blood cell cultures (WBCC), and @entity10733 ( @entity10733 ) plasma levels were measured as two independent immunological parameters in a group of 67 untreated @entity1358 ( @entity1358 ) @entity1 at different clinical stages, and 40 age matched healthy controls. In the blood cell cultures of the @entity5 @entity1 the levels of @entity379 were significantly lower compared to the controls and the values decreased with increasing @entity5 mass. In contrast, @entity10733 plasma levels were significantly higher in the @entity5 @entity1 and increased with @entity5 stage. Additionally serial assessments of these parameters were studied in another group of 15 @entity1 with advanced @entity1358 during treatment with @entity1199 , @entity3027 and @entity1968 according to three different protocols in order to search for any correlation between the biological marker values and the clinical response to treatment. During each 5 day cycle of high dose @entity1199 / @entity3027 combination therapy (protocol 1) @entity379 -levels in the WBCC were markedly decreased, whereas the plasma levels of @entity10733 were increased. During low dose, long-term continuous @entity3027 / @entity1199 administration (protocol 2) in two @entity1 a clear increase of the ex vivo leukocyte @entity379 production was seen for the first 5 and 6 months of treatment, respectively, which could be correlated to stable disease for this time. When progression was diagnosed, @entity379 levels in the WBCC decreased. In the WBCC of the other four @entity1 with progressive @entity379 levels were rather low throughout (< 10 ng/ml) and no clear changes were measured. During low does @entity3027 and @entity10211 therapy in repetitive weekly cycles (protocol 3) two @entity1 had stable disease for 6 and 14 months respectively. In the WBCC cultures of these @entity1 @entity379 production was higher during stable than during progressive disease. The other two @entity1 with @entity5 progression had a very low leukocyte @entity379 production and high plasma levels of @entity10733 . It is concluded that @entity379 levels in WBCC and @entity10733 plasma levels may be useful parameters for the immunological monitoring of therapies with biological response modifiers. Low @entity379 values and high @entity10733 levels may be predictive of @entity5 progression and bad prognosis.

Correlation of clinical and immunological parameters of metastatic @entity1358 @entity1 undergoing therapy with @entity1199 , interferon-alpha and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity10733 :: ('7133', 'Gene') :: ['TNF-receptor p75', 'TNF-R-75'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC'] @entity1968 :: ('MESH:D014212', 'Chemical') :: ['retinoic acid'] @entity379 :: ('3458', 'Gene') :: ['IFN-gamma'] @entity10211 :: ('MESH:D015474', 'Chemical') :: ['13-cis-retinoic acid'] @entity1199 :: ('3558', 'Gene') :: ['IL-2'] @entity3027 :: ('3439', 'Gene') :: ['IFN-alpha']
@entity1968 :: (MESH:D014212,Chemical) :: ['retinoic acid']
